TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Follow the Sutures. A New Procedure for Injection of Botulinum Toxin for Chronic Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic migraine, as defined in the ICHD-3 beta version~* Chronic migraine should have been present for at least ½ year prior to evaluation for study inclusion~* For women of child-bearing potential there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception~* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations~Exclusion Criteria:~* Diseases that are contraindications for use of Botulinum toxin A (Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, other diseases interfering with neuromuscular function)~* Allergy to Botulinum toxin A~* Other primary or secondary headache disorder, including medication overuse headache (MOH). This means that at least one attempt to withdraw acute medication should have been performed earlier, but without success~* Severe depression or other psychiatric disorder that may interfere with the treatment~* Abuse of alcohol or illicit drugs~* Use of more than one headache prophylactic medication, or change in type and dose of prophylactic medication \< 28 days before start of baseline period~* Previous exposure at any time to any botulinum toxin serotype~* Infection at one or more injection site(s)~* Having received extracranial nerve block, cervical facet injection, or other interventional procedure for headache within the prior 3 months~* Use of opioids or barbiturate containing medication(s) \> 10 days per month within the preceding 3 months~* Participating in another trial that might affect the current study~* Should not participate in the opinion of the investigator (e.g. not able to comply with study procedures).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- BoNT-A injected (Type: EXPERIMENTAL): BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring IV antibiotic therapy and with systemic signs of infection diagnosed with ABSSSI.~* Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections~Exclusion Criteria:~* Uncomplicated skin infections~* Severe sepsis or septic shock~* ABSSSI solely due to gram-negative pathogens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TR-701 FA (Type: EXPERIMENTAL): • TR-701 FA IV followed by TR-701 FA tablets
- Linezolid (Type: ACTIVE_COMPARATOR): • Linezolid IV followed by Linezolid Tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Motivational Interviewing and Education Based on Watson's Theory of Human Caring in Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who were receive hemodialysis at Hemodialysis Unit of University Hospital in Antalya, Turkey~* Patients who had 1 and above from Diet And Fluid Non-Adherence Questionnaire total score~* Patients who had 0 or 1 score from 1.2. and 6. questions or 3., 4. and 5. questions in the Modified Morisky Scale.~* Patients who receiving Hemodialysis treatment for at least 3 months~* Patients who were over 18 years of age,~* Patients who had orientation of individual, place and time~* Patients who were literate~* Patients who no barriers to written or verbal communication~* Patients who agree to participate in the study~Exclusion Criteria:~* Patients who had psychiatric disease~* Patients who had diagnosis of malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
- Control Group (Type: NO_INTERVENTION): The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with stable medical conditions for 182 days (26 weeks) after occurrence of cerebral infarction~2. Patients in whom the infarct-related foci was detected by X-ray CT scan or MRI~3. Patients aged 20 to 80 years (inclusive) at time of consent~4. Patients with none of the following cardiac diseases that may be associated with cardiogenic cerebral embolism: mitral stenosis, prosthetic heart valve, endocarditis, myocardial infarction within 6 weeks after occurrence, ventricular aneurysm, endocardial thrombosis, mitral valve prolapse (patients less than 45 years of age in whom no other cause was identified), atrial fibrillation, sick sinus syndrome, idiopathic cardiomyopathy, and patent foramen ovale~5. Patients without asymptomatic cerebral infarction~6. Patients who have neither undergone nor are scheduled to undergo percutaneous transluminal angioplasty or revascularization for the treatment of cerebral infarction~7. Patients without severe disturbances/impairments following occurrence of cerebral~Exclusion Criteria:~1. Patients with hemorrhage or bleeding tendency (hemophilia, capillary fragility, intracranial hemorrhage, hemorrhage in the digestive tract, hemorrhage in the urinary tract, hemoptysis, and hemorrhage in the vitreous body)~2. Pregnant, possibly pregnant, or nursing women~3. Patients with ischemic heart failure~4. Patients with peptic ulcer~5. Patients with severer blood disorders~6. Patients with severe hepatic or renal~7. Patients with malignant neoplasm or patients who have received any therapy for malignant neoplasm within 5 years prior to entering the study~8. Patients with a history of hypersensitivity to salicylic acid formulations or ingredients of cilostazol tablets~9. Patients with aspirin asthma (asthma attacks induced by nonsteroidal antiinflammatory analgesic agents) or a history of aspirin asthma~10. Patients who are being treated with ticlopidine hydrochloride~11. Patients who are participating in another study for an investigational drug~12. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): cilostazol
- 2 (Type: ACTIVE_COMPARATOR): Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dystonia with at least 18 months duration since onset.~* Previously untreated with Botulinum toxin-A (BTX-A) or -B or a minimum of 14 weeks since the last injection.~* TWSTRS score at baseline of: Total score ≥ 30, Severity Sub-Scale score ≥ 15, Disability Sub-Scale score ≥ 3, Pain Sub-Scale score ≥ 2.~Exclusion Criteria:~* Known hypersensitivity to Botulinum toxin (BTX) or related compounds or any component in the study drug formulation (including cow milk protein).~* Pure anterocollis or pure retrocollis.~* In apparent remission from Cervical Dystonia.~* Known clinically significant underlying swallowing or respiratory abnormality which might be exacerbated by BTX treatment.~* Previous poor response to BTX treatment or known presence of BTX neutralising antibodies.~* Previous phenol or alcohol injections into the neck muscles.~* Previous myotomy or denervation surgery involving the neck or shoulder region.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport NG (Type: EXPERIMENTAL): 500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5.
- Dysport (Type: ACTIVE_COMPARATOR): 500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
- Placebo (Type: PLACEBO_COMPARATOR): 1mL administered as, intramuscular injection on day 1 of treatment cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:• Informed consent~* Age \> 18 years~* Performance status 0-1; expected survival ≥ 3 months~* Patient with histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the breast~* Liver metastases not suitable for local treatment~* Extrahepatic disease should be determined by PET-CT-scan.~* No progression on treatment with capecitabine.~* Prior treatment with taxane (adjuvant or for metastatic disease)~* Metastases \< 70 % of the liver~* Neutrophile granulocytes \> 1.5 x 109/l og thrombocytes \> 100 x 109/l~* Bilirubin \< 2.0 x UNL (upper normal limit).~* Creatinine-clearance \> 30 ml/min.~* INR \< 1.6.~* If the patient is HER2-positive:Baseline LVEF ≥ 50 %~Exclusion Criteria:~* History of chemotherapy within the 4-week period prior to the start of trial medication~* Other current or prior malignant disease except adequately treated and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin.~* Previous treatment with oxaliplatin~* Cytotoxic or experimental treatment within a 14 days period before start of trial medication~* The patient is not allowed to participate in other clinical trials.~* Any clinical symptoms suggesting peripheral neuropathy \< or equal to grade 2 or CNS metastases (In case of clinical suspicion on CNS metastases a MR or CT scan should be performed within 4 weeks before inclusion~* Other severe medical conditions e.g. severe cardial disease or AMI \< 1 year~* Presence of diseases which prevent oral therapy.~* Patients with uncontrolled infection~* Pregnant or lactating women~* Women capable of childbearing not using a sufficient non-hormonal method of birth control~* Patients not able to understand the treatment or to collaborate.~* Prior serious or unsuspected reaction after treatment with fluoropyrimidine~* Known prior hypersensitivity reactions to the agents~If the patient is HER2-positive:~* Dyspnoea in due to complication related to malignant disease e.g.lung metastases with lymphangitis or other conditions with need of supportive oxygen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman at least 18 years old~* Diagnosis of metastatic colorectal cancer (mCRC)~* One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based chemotherapy~* Radiologically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last dose of first-line chemotherapy~* At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST~* Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2~* Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses~* Adequate hematologic, renal, and hepatic functions~* Negative pregnancy test within 72 hours of enrollment~* Other protocol-specified criteria may apply~Exclusion Criteria:~* History of or known presence of central nervous system (CNS) metastases~* History of another primary cancer within 5 years of randomization~* Prior irinotecan therapy~* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors~* Any investigational agent or therapy within 30 days before randomization~* Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin~* History of interstitial lung disease or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan~* Active inflammatory bowel disease or other bowel disease causing chronic diarrhea~* Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV), acute or chronic active hepatitis B virus (HBV)~* Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization~* Pregnant or breast-feeding~* Man or woman of child-bearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men)~* Other protocol-specified criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab Plus FOLFIRI (Type: EXPERIMENTAL): Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
- FOLFIRI Alone (Type: ACTIVE_COMPARATOR): Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Zinc in Recurrent Acute Lower Respiratory Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 to 59 months with documented recurrent acute lower respiratory infection i.e., more than two episodes of ALRI in one year or more than three episodes in any time frame.~Exclusion Criteria:~* Children with congenital heart diseases~* Children with congenital anomalies which can cause recurrent chest infection~* Children with Tuberculosis~* Children with bronchial asthma or hyperactive airway disease~* Children with WZS \< -2 of HZS \< -2 as per WHO standards~* Children with any diarrhoeal episode in past 3 months~* Children having receive any zinc supplementation in past 3 months~* Children who did not turn up on follow up and could not be contacted were excluded from the study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Zinc group (Type: EXPERIMENTAL): children with recurrent acute lower respiratory infections receiving zinc supplementation
- Placebo group (Type: PLACEBO_COMPARATOR): children with recurrent acute lower respiratory infections receiving placebo syrup

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological verified non small cell lung cancer 2. Metastatic or locally advanced incurable stage III-IV NSCLC 3. Patients need to be off chemotherapy treatment 4. Evaluable disease according to RECIST V. 1,1 criteria 5. Patients must be HLA-A2 positive 6. Patients \> 18 years old 7. Performance status 0-1 8. Life expectancy of \> 3 months 9. Acceptable bone marrow function, defined as~a. White blood cell count \> 2,5 \* 109 /l b. Neutrophil count\> 1,5 \* 109 /l c. Platelet count \> 75 \* 109/l 10. Creatinin measured \< 2,5 \* upper limit value 11. Acceptable liver function, defined as~1. ASAT \< 100 U/L~2. Bilirubin \< 30 U/L 12. Women with child-bearing potential must have controlled s-hcg before inclusion 13. Patients must provide written informed concent before inclusion 13. Termination of chemotherapy treatment \> 28 days before inclusion~   14. Termination of radiotherapy treatment \> 28 days before inclusion~   15. Inclusion at least \> 4 weeks after complicated gastric surgery~   -~   Exclusion Criteria:~  1. Other malignancies except from non-melanoma skin cancer in the previous 5 years until study inclusion~  2. Brain metastasis are allowed after radical excision, and if the patient at least 1 month afterwards is not in clinical or radiographic progression~  3. Patients with active gastric ulcer disease; patients taking antacid treatment can be included.~  4. Severe medical condition, severe asthma, severe COLD, severe arteriosclerosis or diabetic disease~  5. Acute or chronic infection (ie. HIV, hepatitis, tuberculosis)~  6. Severe allergic reaction or previous anaphylactic shock~  7. Autoimmune diseases (ie. autoimmune neutropenia/thrombopenia, hæmolytic anaemia, systemic lupus erythematosis, Sjøgrens disease, sclerodermia, Goodpastures syndrome, Addisons disease, active Graves disease)~  8. Pregnant or lactating women~  9. Psychiatric disease, which can influence compliance~  10. Known hypersensitivity towards the adjuvance Montanide, the Aldara creme, or adhesive tape.~  11. Treatment with immunosuppressive therapy (ie. dexamethasone, methotrexate)~  12. Treatment with other experimental therapy~  13. Treatment with other anti-cancer therapy, except from treatment of osteoporosis~  14. No systemic chemotherapy, immunotherapy or radiation therapy (except locally) are allowed until 28 days before inclusion.~       -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indeolamine 2,3 deoxygenase (Type: EXPERIMENTAL): To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid and increased fasting serum 7alphaC4 who meet the following:~INCLUSION CRITERIA~* Bowel disease questionnaire (BDQ) - IBS symptoms: Positive by Rome lll criteria~* No restrictions on Hospital Anxiety/Depression Score (HADS).~* Gender: Men or women. Women of childbearing potential will have a negative pregnancy test before initiation of medication.~EXCLUSION CRITERIA~* Use of drugs or agents within the past 1 week or planned use in the subsequent 2 weeks during the study period (Birth control pill, estrogen replacement therapy, and thyroxine replacement are permissible exceptions):~  * Agents that alter GI transit including opioids, narcotics, anticholinergics, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRI) antidepressants.~ * Analgesic drugs including opiates, nonsteroidal anti-inflammatory drugs (NSAID), cyclooxygenase-2 (COX 2) inhibitors~ * Intake of medication that could interfere with the interpretation of the study.~* Female subjects who are pregnant or breast-feeding. Females must be either surgically sterilized, postmenopausal (\>12 months since last menses), or, if of childbearing potential, using reliable methods of contraception as determined by the physician.~* Abdominal surgery (except Appendectomy)~* Patients with known chronic liver disease or history of elevated aspartate aminotransferase (AST)/ alanine transaminase (ALT) 2.0 X upper limit of normal.~  * Bile acid (BA) synthesis and possible false positive or negative fecal bile acid or serum 7alpha-hydroxy-4-cholesten-3-one (7alphaC4) result. If there is no AST or ALT values in the medical record, the study physicians will determine if the tests need to be run.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: OTHER): 1875 mg of Colesevelam orally twice daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete